Madrigal's Resmetirom Approaches PDUFA: The First MASH Drug Could Reshape Hepatology
Madrigal Pharmaceuticals faces an August 14 PDUFA date for resmetirom — the first-ever drug for MASH/NASH. A 30-year hunt for a fatty liver disease treatment comes down to one FDA decision.
July 22, 2026 · Rare Disease · $MDGL